Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Subscribe To Our Newsletter & Stay Updated
